Hyderabad, India and Princeton, NJ, USA. October 26, 2016— Dr. Reddy’s Laboratories Ltd
(BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a
strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of
sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated
New Drug Applications (ANDAs). The portfolio is a mix of filed ANDAs pending approval by the
US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and
comprised of generic injectables administered in hospitals and clinics in the U.S. The combined
sale of branded and generic versions of the products in the U.S. is approximately US$ 1 Billion
MAT for the most recent twelve months ending in August 2016 according to IMS Health*.
Alok Sonig, Executive Vice President and Head of North America said, “We are excited about this
opportunity. Dr. Reddy’s Laboratories has a strong track record in developing, marketing and
distributing generic injectables in the U.S. Our strengths, combined with Gland’s track record of
manufacturing and operational excellence, will help bring affordable medications within reach of
patients and complement our specialty injectables offering in the short-to-medium term.”
Srinivas Sadu, Chief Operating Officer of Gland Pharma added, “We are happy to expand our
collaboration with Dr.Reddy’s for marketing and distribution of Gland Products in US and other Ex
US markets. Dr.Reddy’s has an impressive track record of commercializing injectables products
in the U.S, and we are confident that our partnership will continue to grow.”
Dr. Reddy’s is aggressively developing its US injectable business and recently launched
Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar®.
For more information please visit: www.drreddys.com
